Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy

Antzeko izenburuak

• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  nork: Rangachari, Deepa, et al.
  Argitaratua: (2017)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  nork: Sehgal, Kartik, et al.
  Argitaratua: (2018)
• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  nork: Jorge, Susan E., et al.
  Argitaratua: (2015)
• Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
  nork: Le, Xiuning, et al.
  Argitaratua: (2015)
• De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
  nork: Lucena-Araujo, Antonio R., et al.
  Argitaratua: (2016)